Home / Latest Reports / Glp 1 Receptor Agonist Market

Glp-1 Receptor Agonist Market by Type - Global Industry Analysis & Forecast to 2027

Published On : August 2020 Pages : 150 Category: Pharma & Healthcare Report Code : HC0812321

SEGMENTS & REGIONS:

  • Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa

Glp-1 Receptor Agonist Market by Type (Victoza, Ozempic, Saxenda, Trulicity, Bydureon, Other) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Glp-1 Receptor Agonist Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Glp-1 Receptor Agonist are the drugs for Type- 2 Diabetes, they act on hormones called incretins and causes the pancreas to produce more insulin after eating and helps keep blood glucose levels in the normal range.

Drivers and Restraints

Top-down and bottom-up approaches are used to validate the global market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Regional Insights

The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2021 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

a

Market Classification

·         Glp-1 Receptor Agonist Market, By Type, Estimates and Forecast, 2017-2027 ($Million)

o    Victoza

o    Ozempic

o    Saxenda

o    Trulicity

o    Bydureon

o    Other

·         Glp-1 Receptor Agonist Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)

o    Eli Lilly and Company

o    Sanofi

o    Novo Nordisk A/S

o    AstraZeneca

·         Glp-1 Receptor Agonist Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America Glp-1 Receptor Agonist Market, By Country

o    U.S. Glp-1 Receptor Agonist Market

o    Canada Glp-1 Receptor Agonist Market

o    Mexico Glp-1 Receptor Agonist Market

o    Europe

§  Europe Glp-1 Receptor Agonist Market, By Country

o    Germany Glp-1 Receptor Agonist Market

o    UK Glp-1 Receptor Agonist Market

o    France Glp-1 Receptor Agonist Market

o    Russia Glp-1 Receptor Agonist Market

o    Italy Glp-1 Receptor Agonist Market

o    Rest of Europe Glp-1 Receptor Agonist Market

o    Asia-Pacific

§  Asia-Pacific Glp-1 Receptor Agonist Market, By Country

o    China Glp-1 Receptor Agonist Market

o    Japan Glp-1 Receptor Agonist Market

o    South Korea Glp-1 Receptor Agonist Market

o    India Glp-1 Receptor Agonist Market

o    Southeast Asia Glp-1 Receptor Agonist Market

o    Rest of Asia-Pacific Glp-1 Receptor Agonist Market

o    South America

§  South America Glp-1 Receptor Agonist Market, By Country

o    Brazil Glp-1 Receptor Agonist Market

o    Argentina Glp-1 Receptor Agonist Market

o    Columbia Glp-1 Receptor Agonist Market

o    Rest of South America Glp-1 Receptor Agonist Market

o    Middle East and Africa

§  Middle East and Africa Glp-1 Receptor Agonist Market, By Country

o    Saudi Arabia Glp-1 Receptor Agonist Market

o    UAE Glp-1 Receptor Agonist Market

o    Egypt Glp-1 Receptor Agonist Market

o    Nigeria Glp-1 Receptor Agonist Market

o    South Africa Glp-1 Receptor Agonist Market

o    Rest of MEA Glp-1 Receptor Agonist Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Glp-1 Receptor Agonist  Market, By Type

5.1.     Introduction

5.2.     Global Glp-1 Receptor Agonist  Revenue and Market Share by Type (2017-2021)

5.2.1.  Global Glp-1 Receptor Agonist  Revenue and Revenue Share by Type (2017-2021)

5.3.     Victoza

5.3.1.  Global Victoza Revenue and Growth Rate (2017-2021)

5.4.     Ozempic

5.4.1.  Global Ozempic Revenue and Growth Rate (2017-2021)

5.5.     Saxenda

5.5.1.  Global Saxenda Revenue and Growth Rate (2017-2021)

5.6.     Trulicity

5.6.1.  Global Trulicity Revenue and Growth Rate (2017-2021)

5.7.     Bydureon

5.7.1.  Global Bydureon Revenue and Growth Rate (2017-2021)

5.8.     Other

5.8.1.  Global Other Revenue and Growth Rate (2017-2021)

6.       Glp-1 Receptor Agonist  Market, By Region

6.1.     Introduction

6.2.     Global Glp-1 Receptor Agonist  Revenue and Market Share by Regions

6.2.1.  Global Glp-1 Receptor Agonist  Revenue by Regions (2017-2021)

6.3.     North America Glp-1 Receptor Agonist  by Countries

6.3.1.  North America Glp-1 Receptor Agonist  Revenue and Growth Rate (2017-2021)

6.3.2.  North America Glp-1 Receptor Agonist  Revenue (Million USD) by Countries (2017-2021)

6.3.3.  United States

6.3.3.1.  United States Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.3.4.  Canada

6.3.4.1.  Canada Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.3.5.  Mexico

6.3.5.1.  Mexico Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.4.     Europe Glp-1 Receptor Agonist  by Countries

6.4.1.  Europe Glp-1 Receptor Agonist  Revenue and Growth Rate (2017-2021)

6.4.2.  Europe Glp-1 Receptor Agonist  Revenue (Million USD) by Countries (2017-2021)

6.4.3.  Germany

6.4.3.1.  Germany Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.4.4.  France

6.4.4.1.  France Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.4.5.  UK

6.4.5.1.  UK Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.4.6.  Russia

6.4.6.1.  Russia Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.4.7.  Italy

6.4.7.1.  Italy Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.4.8.  Rest of Europe

6.4.8.1.  Rest of Europe Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.5.     Asia-Pacific Glp-1 Receptor Agonist  by Countries

6.5.1.  Asia-Pacific Glp-1 Receptor Agonist  Revenue and Growth Rate (2017-2021)

6.5.2.  Asia-Pacific Glp-1 Receptor Agonist  Revenue (Million USD) by Countries (2017-2021)

6.5.3.  China

6.5.3.1.  China Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.5.4.  Japan

6.5.4.1.  Japan Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.5.5.  Korea

6.5.5.1.  Korea Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.5.6.  India

6.5.6.1.  India Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.5.7.  Southeast Asia

6.5.7.1.  Southeast Asia Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.5.8.  Rest of Asia-Pacific

6.5.8.1.  Rest of Asia-Pacific Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.6.     South America Glp-1 Receptor Agonist  by Countries

6.6.1.  South America Glp-1 Receptor Agonist  Revenue and Growth Rate (2017-2021)

6.6.2.  South America Glp-1 Receptor Agonist  Revenue (Million USD) by Countries (2017-2021)

6.6.3.  Brazil

6.6.3.1.  Brazil Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.6.4.  Argentina

6.6.4.1.  Argentina Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.6.5.  Columbia

6.6.5.1.  Columbia Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.6.6.  Rest of South America

6.6.6.1.  Rest of South America Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.     Middle East and Africa Glp-1 Receptor Agonist  by Countries

6.7.1.  Middle East and Africa Glp-1 Receptor Agonist  Revenue and Growth Rate (2017-2021)

6.7.2.  Middle East and Africa Glp-1 Receptor Agonist  Revenue (Million USD) by Countries (2017-2021)

6.7.3.  Saudi Arabia

6.7.3.1.  Saudi Arabia Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.4.  United Arab Emirates

6.7.4.1.  United Arab Emirates Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.5.  Egypt

6.7.5.1.  Egypt Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.6.  Nigeria

6.7.6.1.  Nigeria Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.7.  South Africa

6.7.7.1.  South Africa Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.8.  Turkey

6.7.8.1.  Turkey Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.  Rest of Middle East and Africa Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2017-2021)

7.       Company Profiles

7.1.     Eli Lilly and Company

7.1.1.  Business Overview

7.1.2.   Service Portfolio

7.1.3.  Strategic Developments

7.1.4.  Financial Overview

7.2.     Sanofi

7.2.1.  Business Overview

7.2.2.   Service Portfolio

7.2.3.  Strategic Developments

7.2.4.  Financial Overview

7.3.     Novo Nordisk A/S

7.3.1.  Business Overview

7.3.2.   Service Portfolio

7.3.3.  Strategic Developments

7.3.4.  Financial Overview

7.4.     AstraZeneca

7.4.1.  Business Overview

7.4.2.   Service Portfolio

7.4.3.  Strategic Developments

7.4.4.  Financial Overview

8.       Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.1.     Global Glp-1 Receptor Agonist  Revenue (Millions USD) and Growth Rate (2022-2027)

8.2.     Glp-1 Receptor Agonist  Market Forecast by Regions (2022-2027)

8.2.1.  North America Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.1.1.  United States Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.1.2.  Canada Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.1.3.  Mexico Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.  Europe Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.1.  Germany Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.2.  France Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.3.  UK Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.4.  Russia Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.5.  Italy Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.2.6.  Rest of Europe Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.  Asia-Pacific Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.1.  China Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.2.  Japan Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.3.  Korea Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.4.  India Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.5.  Southeast Asia Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.3.6.  Rest of Asia-Pacific Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.4.  South America Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.4.1.  Brazil Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.4.2.  Argentina Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.4.3.  Columbia Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.4.4.  Rest of South America Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.  Middle East and Africa Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.1.  Saudi Arabia Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.2.  United Arab Emirates Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.3.  Egypt Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.4.  Nigeria Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.5.  South Africa Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.6.  Turkey Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.2.5.7.  Rest of Middle East and Africa Glp-1 Receptor Agonist  Market Forecast (2022-2027)

8.3.     Glp-1 Receptor Agonist  Market Forecast by Type (2022-2027)

8.3.1.  Glp-1 Receptor Agonist  Forecast by Type (2022-2027)

8.3.2.  Glp-1 Receptor Agonist  Market Share Forecast by Type (2022-2027)

List of Tables

List of Tables and Figures:

Figure United States Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Glp-1 Receptor Agonist Revenue and Revenue Share by Type (2017-2019)
Figure Global Victoza Revenue and Growth Rate (2017-2019)
Figure Global Ozempic Revenue and Growth Rate (2017-2019)
Figure Global Saxenda Revenue and Growth Rate (2017-2019)
Figure Global Trulicity Revenue and Growth Rate (2017-2019)
Figure Global Bydureon Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Glp-1 Receptor Agonist Revenue by Regions (2017-2019)
Figure North America Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure North America Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure North America Glp-1 Receptor Agonist by Countries (2017-2019)
Figure North America Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure United States Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure United States Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Canada Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Mexico Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Europe Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure Europe Glp-1 Receptor Agonist by Countries (2017-2019)
Figure Europe Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure Germany Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Germany Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure France Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure UK Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Russia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Italy Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of Europe Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist by Countries (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure China Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure China Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Japan Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Korea Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure India Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Southeast Asia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure South America Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure South America Glp-1 Receptor Agonist by Countries (2017-2019)
Figure South America Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Brazil Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Argentina Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Columbia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of South America Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist by Countries (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Saudi Arabia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure United Arab Emirates Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Egypt Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Nigeria Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure South Africa Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Turkey Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Table Eli Lilly and Company Glp-1 Receptor Agonist Financial Overview
Table Sanofi Glp-1 Receptor Agonist Financial Overview
Table Novo Nordisk A/S Glp-1 Receptor Agonist Financial Overview
Table AstraZeneca Glp-1 Receptor Agonist Financial Overview
Figure Global Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2019-2027)
Table Glp-1 Receptor Agonist Market Forecast by Regions (2019-2027)
Figure North America Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure United States Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Canada Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Mexico Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Europe Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Germany Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure France Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure UK Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Russia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Italy Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of Europe Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Asia-Pacific Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure China Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Japan Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Korea Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure India Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Southeast Asia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure South America Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Brazil Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Argentina Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Columbia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of South America Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Middle East and Africa Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Saudi Arabia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure United Arab Emirates Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Egypt Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Nigeria Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure South Africa Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Turkey Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Global Glp-1 Receptor Agonist Forecast by Type (2019-2027)
Figure Global Glp-1 Receptor Agonist Market Share Forecast by Type (2019-2027)
Figure Global Glp-1 Receptor Agonist Forecast by Type (2019-2027)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

Request Sample Enquire Before Buying Request for Customization

Request Sample